Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CATX Perspective Therapeutics	$3.76 +3.9%	$2.82	$1.60 ▼ $16.55	$279.10M	1.09	1.07 million shs	4.16 million shs
NNOX Nano-X Imaging	$5.23 -2.8%	$5.22	$3.75 ▼ $11.00	$302.19M	1.99	1.74 million shs	3.05 million shs
SNWV Sanuwave Health	$29.95 -9.4%	$30.00	$5.17 ▼ $39.50	$256.37M	1.19	143,926 shs	955,364 shs
VANI Vivani Medical	$1.32 +0.8%	$1.12	$0.91 ▼ $11.40	$78.20M	2.93	100,277 shs	124,810 shs

Reduce the Risk

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CATX Perspective Therapeutics	0.00%	+8.67%	+46.30%	+76.53%	-62.29%
NNOX Nano-X Imaging	0.00%	+4.81%	+2.35%	+4.81%	-28.75%
SNWV Sanuwave Health	0.00%	-11.07%	+13.45%	-15.32%	+2,994,999,900.00%
VANI Vivani Medical	0.00%	+4.76%	+6.43%	+25.71%	+4.76%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CATX Perspective Therapeutics	2.3059 of 5 stars	3.6	1.0	0.0	0.0	3.1	2.5	0.0
NNOX Nano-X Imaging	2.3492 of 5 stars	3.5	2.0	0.0	0.0	3.8	0.0	0.6
SNWV Sanuwave Health	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
VANI Vivani Medical	3.3402 of 5 stars	3.5	5.0	0.0	0.0	2.2	3.3	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CATX Perspective Therapeutics	3.18	Buy	$12.56	233.92% Upside
NNOX Nano-X Imaging	3.00	Buy	$9.50	81.64% Upside
SNWV Sanuwave Health	0.00	N/A	N/A	N/A
VANI Vivani Medical	3.00	Buy	$4.00	203.03% Upside

Current Analyst Ratings Breakdown

Latest VANI, CATX, NNOX, and SNWV Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/23/2025	CATX Perspective Therapeutics	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00 ➝ $12.00
6/23/2025	CATX Perspective Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$11.00
6/6/2025	NNOX Nano-X Imaging	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
6/3/2025	CATX Perspective Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Outperform ➝ Moderate Buy	$15.00 ➝ $16.00
5/23/2025	NNOX Nano-X Imaging	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$15.00 ➝ $10.00
5/22/2025	NNOX Nano-X Imaging	Alliance Global Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
5/19/2025	VANI Vivani Medical	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.00 ➝ $4.00
5/14/2025	CATX Perspective Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$10.00 ➝ $8.00
5/13/2025	CATX Perspective Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$11.00
4/17/2025	NNOX Nano-X Imaging	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$15.00 ➝ $15.00
4/16/2025	VANI Vivani Medical	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.00 ➝ $4.00

(Data available from 6/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CATX Perspective Therapeutics	N/A	N/A	N/A	N/A	$2.67 per share	N/A
NNOX Nano-X Imaging	$11.28M	26.79	N/A	N/A	$3.27 per share	1.60
SNWV Sanuwave Health	$32.63M	7.86	N/A	N/A	($1.49) per share	-20.10
VANI Vivani Medical	N/A	N/A	N/A	N/A	$0.30 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CATX Perspective Therapeutics	-$46.51M	N/A	0.00	N/A	N/A	-4,096.66%	-27.40%	-23.16%	8/11/2025 (Estimated)
NNOX Nano-X Imaging	-$53.52M	-$0.90	N/A	N/A	N/A	-472.19%	-30.92%	-27.73%	8/19/2025 (Estimated)
SNWV Sanuwave Health	-$31.37M	-$4.56	N/A	∞	N/A	-89.86%	N/A	-145.76%	N/A
VANI Vivani Medical	-$23.49M	-$0.43	N/A	N/A	N/A	N/A	-133.07%	-56.50%	8/12/2025 (Estimated)

Latest VANI, CATX, NNOX, and SNWV Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/22/2025	Q1 2025	NNOX Nano-X Imaging	-$0.23	-$0.21	+$0.02	-$0.21	$3.98 million	$3.00 million
5/13/2025	Q1 2025	VANI Vivani Medical	-$0.10	-$0.11	-$0.01	-$0.11	N/A	N/A
5/9/2025	Q1 2025	SNWV Sanuwave Health	N/A	-$0.66	N/A	-$0.66	N/A	$9.34 million
3/31/2025	Q4 2024	NNOX Nano-X Imaging	-$0.15	-$0.23	-$0.08	-$0.23	$3.80 million	$3.00 million
3/31/2025	Q4 2024	VANI Vivani Medical	-$0.10	-$0.11	-$0.01	-$0.11	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CATX Perspective Therapeutics	N/A	N/A	N/A	N/A	N/A
NNOX Nano-X Imaging	N/A	N/A	N/A	N/A	N/A
SNWV Sanuwave Health	N/A	N/A	N/A	N/A	N/A
VANI Vivani Medical	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CATX Perspective Therapeutics	N/A	9.60	9.60
NNOX Nano-X Imaging	N/A	5.30	5.16
SNWV Sanuwave Health	N/A	0.40	0.28
VANI Vivani Medical	N/A	2.40	2.40

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CATX Perspective Therapeutics	54.66%
NNOX Nano-X Imaging	21.49%
SNWV Sanuwave Health	42.53%
VANI Vivani Medical	6.78%

Insider Ownership

Company	Insider Ownership
CATX Perspective Therapeutics	3.72%
NNOX Nano-X Imaging	N/A
SNWV Sanuwave Health	36.60%
VANI Vivani Medical	46.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CATX Perspective Therapeutics	70	74.23 million	65.21 million	Optionable
NNOX Nano-X Imaging	190	57.78 million	N/A	Optionable
SNWV Sanuwave Health	40	8.56 million	5.43 million	N/A
VANI Vivani Medical	20	59.24 million	31.76 million	Optionable

VANI, CATX, NNOX, and SNWV Headlines

Recent News About These Companies

Vivani Medical shareholders elect board and approve key proposals at annual meeting - Investing.com

June 27 at 4:55 AM | investing.com

Vivani Medical Appoints Anthony Baldor as Chief Financial Officer

June 11, 2025 | manilatimes.netM

Vivani Medical to Present at the 2025 BIO International Convention

June 11, 2025 | finance.yahoo.com

Vivani Stock Gains After Announcing Spin-Off Plans for Cortigent Unit

June 2, 2025 | zacks.com

Companies To Watch: Vivani Medical

May 30, 2025 | lifescienceleader.comL

Vivani files with SEC to spin off neurostim business, focus on drug delivery implants

May 29, 2025 | massdevice.com

Vivani Medical Announces Filing of Form 10 Registration Statement for Planned Spin-Off of Cortigent Neurostimulation Business to Vivani Shareholders

May 29, 2025 | finance.yahoo.com

Vivani Medical Reports Q1 2025 Results and Strategic Updates

May 19, 2025 | tipranks.com

Vivani Medical, Inc.: Vivani Medical Provides Business Update Including $3M Equity Financing and Reports First Quarter 2025 Financial Results

May 15, 2025 | finanznachrichten.de

Vivani Medical, Inc. Reports Successful Initial Data from LIBERATE-1™ Study and Secures $3M in Equity Financing

May 13, 2025 | quiverquant.comQ

Vivani Medical Provides Business Update Including $3M Equity Financing and Reports First Quarter 2025 Financial Results

May 13, 2025 | globenewswire.com

Vivani Medical CEO to Present on Innovative Drug Delivery Solutions at AAPS Virtual Workshop

May 9, 2025 | nasdaq.com

Vivani Medical to Present at the American Association of Pharmaceutical Scientists' “Beyond GLP1s: Where the Science will Take Business Next” Virtual Workshop

May 7, 2025 | globenewswire.com

Vivani Medical to Participate in Virtual Fireside Chat Hosted by H.C. Wainwright & Company

April 16, 2025 | finance.yahoo.com

Vivani Medical, Okava expand collaboration to develop OKV-119 for dogs

April 16, 2025 | markets.businessinsider.com

Vivani Medical and Okava Expand Collaboration to Develop OKV-119 for Dogs, Targeting Metabolic Health and Longevity

April 15, 2025 | globenewswire.com

Gregg Williams Purchases 18,529 Shares of Vivani Medical, Inc. (NASDAQ:VANI) Stock

April 12, 2025 | insidertrades.com

Vivani Medical, Inc. (NASDAQ:VANI) Director Purchases $33,660.00 in Stock

April 9, 2025 | insidertrades.com

Weight loss implants to increase compliance and cut admin burden for patients

April 3, 2025 | finance.yahoo.com

Vivani Medical Reports 2024 Financial Results and Business Progress

March 31, 2025 | tipranks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
By Dan Schmidt | June 20, 2025
View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
By Gabriel Osorio-Mazilli | June 23, 2025
View BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
Intel's Turnaround Strategy Shifts From Planning to Attack Mode
By Jeffrey Neal Johnson | June 20, 2025
View Intel's Turnaround Strategy Shifts From Planning to Attack Mode
3 Semiconductor Stocks Poised to Surge on AI Spending
By Chris Markoch | June 25, 2025
View 3 Semiconductor Stocks Poised to Surge on AI Spending
These 3 Stocks Are Buying Back Billions in Shares
By Leo Miller | June 3, 2025
View These 3 Stocks Are Buying Back Billions in Shares

VANI, CATX, NNOX, and SNWV Company Descriptions

Perspective Therapeutics NYSE:CATX

$3.76 +0.14 (+3.87%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$3.74 -0.02 (-0.66%)

As of 04:12 AM Eastern

Perspective Therapeutics, Inc., together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma. Perspective Therapeutics, Inc. has a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is headquartered in Seattle, Washington.

Nano-X Imaging NASDAQ:NNOX

$5.23 -0.15 (-2.79%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$5.27 +0.04 (+0.76%)

As of 04:35 AM Eastern

Nano-X Imaging Ltd. develops a commercial-grade tomographic imaging device with a digital X-ray source. The company provides teleradiology services and develops artificial intelligence applications to be used in real-world medical imaging applications. Its X-ray source is based on a digital micro-electro-mechanical systems semiconductor cathode. The company's solutions include Nanox Multi Source System comprising Nanox.ARC, a medical tomographic imaging system incorporating its digital X-ray source, and Nanox. CLOUD, a platform which employs a matching engine to match medical images to radiologists that provides image repository, connectivity to diagnostic assistive AI systems, billing, and reporting. It also offers Nanox.MARKETPLACE, which connects imaging facilities with radiologists and enables radiologists to provide, as well as customers to obtain remote interpretations of imaging data; artificial intelligence (AI)-based software imaging solutions to hospitals, health maintenance organizations, integrated delivery networks, pharmaceutical companies, and insurers that are designed to identify or predict undiagnosed or underdiagnosed medical conditions through the mining of data included in images of existing computed tomography scans for osteoporosis and cardiovascular disease; Teleradiology Services, which provide imaging interpretation services for radiology practices, hospitals, medical clinics, diagnostic imaging centers, urgent care facilities; and multi-specialty physician groups, contracts, and radiology readings. The company is headquartered in Petach Tikva, Israel.

Sanuwave Health NASDAQ:SNWV

$29.95 -3.09 (-9.35%)

As of 06/27/2025 04:00 PM Eastern

SANUWAVE Health, Inc., a shock wave technology company, researches, develops, and commercializes noninvasive, high-energy, and acoustic shock waves for regenerative medicine and other applications in the United States and internationally. Its shockwaves are used to produce a biological response resulting in the body healing itself through the repair and regeneration of tissue, and musculoskeletal and vascular structures. The company's lead regenerative product is the dermaPACE device for treating diabetic foot ulcers. Its portfolio of healthcare products and product candidates activate biologic signaling and angiogenic responses, including new vascularization and microcirculatory improvement, which helps to restore the body's normal healing processes and regeneration. The company also focuses on applying its Pulsed Acoustic Cellular Expression technology in wound healing, orthopedic, plastic/cosmetic, and cardiac conditions. In addition, it offers UltraMIST, non-contact and non-thermal ultrasound therapy device used to treat diabetic foot ulcers, pressure ulcers, venous leg ulcers, deep tissue pressure injuries, and surgical wounds; and orthoPACE system to treat tendinopathies and acute and nonunion fractures. The company was founded in 2005 and is headquartered in Suwanee, Georgia.

Vivani Medical NASDAQ:VANI

$1.32 +0.01 (+0.76%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$11.40 +10.08 (+763.64%)

As of 04:00 AM Eastern

Vivani Medical, Inc., a clinical stage company, develops various implants that treat chronic diseases with high unmet medical need. It engages in developing a portfolio of miniature drug implants to deliver minimally fluctuating drug profiles; and implantable visual prostheses devices to deliver useful artificial vision to blind individuals. The company is headquartered in Emeryville, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time